The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.
 
Raphael Eric Steiner
Research Funding - BMSi; GlaxoSmithKline; Rafael Pharmaceuticals; Seagen
 
Paolo Strati
Consulting or Advisory Role - ADC Therapeutics; Genentech/Roche; TG Therapeutics
Research Funding - ALX Oncology; AstraZeneca
 
Christopher Flowers
Consulting or Advisory Role - Abbvie; Bayer; BeiGene; Celgene; Denovo Biopharma; Epizyme; Genentech/Roche; Gilead Sciences; Karyopharm Therapeutics; Pharmacyclics/Janssen; Spectrum Pharmaceuticals
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Alimera Sciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Millennium (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst); Xencor (Inst)
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Athenex; Bluebird Bio; Bristol-Myers Squibb; Calibr; Gilead Sciences; Incyte; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Sana Biotechnology; Sellas Life Sciences
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Kite, a Gilead company; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy; Royalty income from Takeda Pharmaceuticals
 
Michael Richard Green
Stock and Other Ownership Interests - KDAc Therapeutics
Honoraria - Daiichi Sankyo Europe GmbH; Monte Rosa Therapeutics; Tessa Therapeutics
Research Funding - Abbvie; Allogene Therapeutics; Kite/Gilead; Sanofi
 
Loretta J. Nastoupil
Honoraria - ADC Therapeutics; Bayer; Bristol-Myers Squibb; Celgene; Epizyme; Genmab; Gilead Sciences; Janssen Oncology; Morphosys; Novartis; Pfizer; Takeda; TG Therapeutics
Research Funding - Allogene Therapeutics; Caribou Biosciences; Celgene; Epizyme; Genentech/Roche; Gilead Sciences; IgM Biosciences; Janssen Biotech; Novartis; Takeda; TG Therapeutics
 
Fredrick B. Hagemeister
Consulting or Advisory Role - Genentech
 
Lei Feng
No Relationships to Disclose
 
Sairah Ahmed
Honoraria - Novartis; Seagen
Consulting or Advisory Role - Myeloid Therapeutics; Sanofi; Tessa Therapeutics
Research Funding - Merck (Inst); Seagen (Inst); Tessa Therapeutics (Inst)
 
Ranjit Nair
No Relationships to Disclose
 
Luis Fayad
Consulting or Advisory Role - EUSA Pharma; medicamenta ecuatoriana; Roche
 
Hun Ju Lee
Honoraria - Aptitude Health; Cancer Experts Now; Century Therapeutics; Curio Science
Consulting or Advisory Role - BMS; Guidepoint Global
Research Funding - BMS; Celgene; Celgene; Oncternal Therapeutics; Seagen; Takeda
 
Maria Alma Rodriguez
No Relationships to Disclose
 
Jason Westin
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Amgen; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Curis; Forty Seven; Genentech/Roche; Iksuda Therapeutics; IMV; Janssen Scientific Affairs; Karyopharm Therapeutics; Kite/Gilead; Merck; Monte Rosa Therapeutics; MorphoSys; Novartis; Umoja Biopharma
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Curis; Forty Seven; Genentech; Janssen; Kite/Gilead; MorphoSys; Novartis